2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.

Van Den Neste, Eric;Martiat, P.;Mineur, P.;Delannoy, André;Ferrant, Augustin;et.al.
(1998) Annals of hematology — Vol. 76, n° 1, p. 19-23 (1998)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 147.68 KB

Details

Authors
  • Author
  • Martiat, P.
    Author
  • Mineur, P.
    Author
  • Delannoy, AndréUCLouvain
    Author
  • Doyen, ChantalUCLouvain
    Author
  • Michaux, Jean-LouisUCLouvain
    Author
  • Ferrant, AugustinUCLouvain
    Author
Show more
Abstract
2-Chlorodeoxyadenosine (2-CdA) is a purine analogue which has proved to be active in acute myeloid leukemia (AML), especially in children. In adults, results yielded by 2-CdA alone or with ara-C were less encouraging. Here we report on the efficacy of 2-CdA with or without daunorubicin (DNR) in 19 relapsing or refractory adult AML patients, with a median age of 57 years. 2-CdA was administered as a continuous infusion to all patients at a dose of 0.1 mg/kg per day for 7 days. For 14 patients, DNR was added at a dose of 50 mg/m2 per day on days 5, 6, and 7. Antileukemic activity was observed in all the patients, but no single complete remission was achieved. One patient had a long-lasting partial response (response rate=5%). The remaining patients died of progressive AML (n=7), uncontrollable infection with persistent disease (n=10), and cerebral hemorrhage (n=1). Median survival from start of 2-CdA therapy was 56 days. Long-lasting neutropenia and transfusion-dependent thrombopenia were encountered in all 16 evaluable patients. Grade 4 hepatic toxicity occurred in one patient. Other side effects included nausea in six, mucositis in three, and mental disturbances in three patients. Compared with 2-CdA alone, the addition of DNR to 2-CdA changed neither the response rate nor the toxicities. In conclusion, our data do not support the use of 2-CdA +/- DNR for relapsing or refractory adult AML patients, at least as used in the present regimen.
Affiliations

Citations

Van Den Neste, E., Martiat, P., Mineur, P., Delannoy, A., Doyen, C., Zenebergh, A., Michaux, J.-L., & Ferrant, A. (1998). 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Annals of hematology, 76(1), 19-23. https://doi.org/10.1007/s002770050355 (Original work published 1998)